Microbubble treatment of liver cancer

Share This Post

Hepatitis C is primarily to blame for liver cancer, one of the deadliest cancers. In addition, complications of fatty liver disease are also a cause of liver cancer. At present, researchers are trying to treat liver cancer by improving microbubbles. Microbubbles, including the sturdy outer shell and small gas bubbles inside the gas, insert glass radiation beads into the liver, and then inject the microbubbles into the blood. It is usually used in combination with radiation therapy for the treatment of advanced liver cancer.

Dr. John Eisenbrey, a radiology researcher at Thomas Jefferson University, said, “focusing the ultrasound beam on the liver tumor, the bubbles participate in the blood circulation in the body. The ultrasound only focuses on the tumor itself, and it does not affect the surrounding healthy tissue, and only generates bubbles inside the tumor. The blood supply through the catheter is only deposited in the tumor. When the bubbles burst, it will enhance the radiation effect. This therapy is to destroy the blood supply and starve the tumor, and then the tumor begins to shrink over time. It is still in The early stages of clinical trials have shown good results.

At present, researchers are using commercial bubbles outside the label, and at the same time working with chemists and engineers to put chemotherapy drugs, oxygen and other compositions into microbubbles to circulate in the blood to achieve the purpose of shrinking tumors and extending the life of patients.

Subscribe To Our Newsletter

Get updates and never miss a blog from Cancerfax

More To Explore

Targeting FGFR4 and CD276 with CAR T-cells demonstrates a strong antitumor impact against children rhabdomyosarcoma
CAR T-Cell therapy

Targeting FGFR4 and CD276 with CAR T-cells demonstrates a strong antitumor impact against children rhabdomyosarcoma

Chimeric antigen receptor (CAR) T-cells that specifically target Fibroblast Growth Factor Receptor 4 (FGFR4), a surface tyrosine receptor that is extensively expressed in rhabdomyosarcoma (RMS), are now undergoing clinical research. However, the effectiveness of these CAR T-cells may be hindered by tumor heterogeneity and inadequate activation. In this study, we present a method to enhance the co-stimulatory and targeting characteristics of a FGFR4 CAR through an optimization process. We substituted the hinge and transmembrane domain of CD8 as well as the 4-1BB co-stimulatory domain with the corresponding domains of CD28. The CARs produced exhibit heightened anti-tumor efficacy in multiple RMS xenograft models, with the exception of the RMS559 cell line, which is known for its aggressive nature.

Need help? Our team is ready to assist you.

We wish a speedy recovery of your dear and near one.

Start chat
We Are Online! Chat With Us!
Scan the code
Hello,

Welcome to CancerFax !

CancerFax is a pioneering platform dedicated to connecting individuals facing advanced-stage cancer with groundbreaking cell therapies like CAR T-Cell therapy, Gene therapy, TIL therapy, and clinical trials worldwide.

Let us know what we can do for you.

1) CAR T-Cell therapy
2) Gene therapy
3) Gamma-Delta T Cell therapy
4) TIL therapy
5) NK Cell therapy